Showing posts with label PacBio. Show all posts
Showing posts with label PacBio. Show all posts

23 December 2011

NGS Hype War



Who’s winning the NGS hype war? 

A few years ago it was PacBio – they were going to sequence a genome in 15 minutes. Currently it would take them >90 days and cost ~$225k. (They’re now more sensibly focusing on the advantages of long reads and directly reading modified nucleotides.)  

Ion Torrent took over the reigns of ‘hype king’ with the launch of the Personal Genome Machine.  They are building on the trillion dollar investments of the silicon wafer industry and promising 10x improvements every six months, to infinity and beyond! The most recent promise is a $1000 genome in two hours in 2012. In all fairness, they’ve kept up their promises over the past 12 months. The “10MB” 314 chip is now producing up to 40MB. They launched the 10x improved “100MB” 316 chip over the summer, and it’s now routinely generating >200MB of data. The “1GB” 318 chip hasn’t launched yet, but it seems reasonable that they’ll be able to hit their target. I haven’t heard anything about their next chip (what would/could be the 320 chip), but I suspect they’ll have lots to say at Marco Island.

So Ion Torrent is clearly currently winning the hype war, but is there a contender? Mabye.  

Genia is a new start-up out of Menlo Park. They’re talking about the $100 genome (the $1000 genome is so 2011) and they’re calling themselves the “Last-Gen Sequencing” company. Apparently their technology is so revolutionary there won’t be a need for anything else. Just a heads up to anyone else developing their own technology, you might as well stop. Genia’s got it covered. No, they don’t have any instruments to sell just yet. And, no, they technically haven’t actually produced any sequence yet. But just you wait. They hype has just begun!

30 September 2011

What's the NGS Buzz?

There's been quite a bit of 'next-gen' sequencing news lately (some of it positive, some of it pretty negative). I thought I'd take a stab at ranking them in terms of their "buzz" - how much people are talking about them, excitement around updates, etc. It is very subjective and definitely NOT an attempt at ranking their usefulness/performance (which would be highly application specific). Feel free to let me know how wrong I am in the comments section.

(I inexplicably left out Complete Genomics - now corrected)


 
Platform Comments Buzz Factor Trend
Ion Torrent Lots of promises, excitement and chatter
Lots of blogs analyzing data
10
MiSeq Data starting to trickle out
Mostly in a battle with Ion Torrent
6
GnuBio Completely backed off their "$30 WGS" claims
Interest picking back up now that they're in beta testing
5
Complete Genomics Still in the news, in a death battle with ILMN and BGI 5
HiSeq Dominant (if boring) NGS workhorse 4
Oxford Nanopore Not much news
Initial excitement waning
Waiting for next (first?) big announcement
3
Pacific Biosciences Only news is bad news
Management overestimated market adoption of PacBio
Laid off 28% of workforce (ouch!)
3
SOLiD Has become the ugly stepsister of Ion Torrent
Management says "putting all chips into Ion Torrent" and "(light based seq) is nearing the end"
2
454 Not a lot of news since FLX+
Not much in the way of public discussion
2



16 February 2011

AGBT's biggest loser was...


Twitter!

Seriously, the AGBT organizers appeared to be caught off guard by the popularity of tweeting/blogging about the various talks. Many thanks to the presenters who allowed tweeting and to the many attendees who took the time to tweet and blog about them. I found it enormously helpful as it allowed me to attend the meeting vicariously. I've listed some of the blog resources at the end (which also contain good info on the research talks).

The general consensus seems to be that the meeting was good but that there really wasn't anything groundbreaking this year. The commercial players either already announced their good news back in January, had nothing to say or weren't ready to say anything just yet.

The Established Players:

There really was nothing new for the meeting as they had already announced the program for achieving 600GB with HiSeq2000, the internal 1TB runs and the new MiSeq platform. Illumina was a fairly popular tweet/blog topic (second highest coverage) with most people either focusing on MiSeq, HiSeq's data output or Illumina's general market dominance. The only real negative that came up was the run failure rate at Harvard. Illumina had a moderate presence in the twitterverse, sending out an average # of tweets to attendees.

Like Illumina, they didn't really have anything new to say about their SOLiD platform. They were, however, the king of the tweets, sending out more than all of the other sequencing vendors combined. The attendees weren't quite so vocal. Combining tweets for both SOLiD and Ion Torrent (see below), they had just the third highest coverage. As for news, it seems that Life is really starting to position SOLiD as system of choice for the cancer genome market.

Bucking the trend, Complete Genomics did save some big news for the meeting. They have created a public database containing 40 complete genomes with the promise of 20 more in March. The company tweeted an average amount and received some back (#4), most of which was excitement around the public dataset.

Hello? Does anyone have anything to say about 454? <crickets>. Nothing directly from the company and just a handful of tweets from the attendees. Maybe next year?

The Hopefuls:

Life didn't really have any announcements about Ion Torrent, but people were eager to see the data in the presentations. They seemed pleased with the low GC bias but perhaps a little disappointed with the error rates.

The company didn't send out any tweets, but they win the prize for the greatest interest from the twitterverse – almost double the #2 tweet getter. However, a big chunk of that was about the movie they showed (which some described as too simplistic for the AGBT audience while others described it as a giant 30 min ad for PacBio).

ONP tweeted an average amount, but they didn't have any big announcements. There wasn't too much tweeting about them since no one has their hands on this instrument yet, but those who did comment seemed quite positive about their GridION system and were eager to see some real data.

Nothing from the company, but a few people out there were eager to see how this system will perform.

About the same – nothing much out there yet, but some are waiting.

The Head Scratcher:

Agilent was the “Gold” sponsor (just below Life, which nabbed “Platinum”) - something that costs big bucks (around $100k, I think). However, at least in the twitterverse and the blogosphere, they were just about a non-entity. There were no official tweets from the company and their only announcement was about their new RNA target enrichment kit. A nice addition to the market, but I'm not sure if that news was worthy of the gold sponsorship purchase.


AGBT Summaries (a big thanks to you all!):

Keith Robison at Omics! Omics!
Prithwish at Omically Speaking (part 1, part 2)
Kevin Davies of BioIT World at NGSLeaders
J Ireland at 5AM